Natriuretic peptides as biomarkers in heart failure

Journal of Investigative Medicine

Volumn 61, Issue 6, 2013, Pages 950-955

  Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biology; Diagnosis; Natriuretic peptides; Prognosis; Therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DENDRO ASPIS NATRIURETIC PEPTIDE; ENDOTHELIN 1; INTERLEUKIN 1BETA; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; UNCLASSIFIED DRUG; URODILATIN; V TYPE NATRIURETIC PEPTIDE.;

AGE DISTRIBUTION; CARDIOVASCULAR MORTALITY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; ENZYMATIC DEGRADATION; EVIDENCE BASED MEDICINE; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE PRESSURE; HUMAN; KIDNEY DYSFUNCTION; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; OLIGOMERIZATION; PARACRINE SIGNALING; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN SECRETION; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; STEADY STATE; MOLECULAR EVOLUTION; PROTEIN DETERMINATION; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES;

EID: 84888317394     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182946b69     Document Type: Conference Paper

References (56)

1. Patel JB, Valencik ML, Pritchett AM, et al. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol. 2005;289(2):H777YH784.
2. Tamura N, Ogawa Y, Yasoda A, et al. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes. J Mol Cell Cardiol. 1996;28(8):1811-1815.
3. Takei Y. Does the natriuretic peptide system exist throughout the animal and plant kingdom? Comp Biochem Physiol B Biochem Mol Biol. 2001;129(2-3):559- 573.
4. LaPointe MC, Wu G, Garami M, et al. Tissue-specific expression of the human brain natriuretic peptide gene in cardiac myocytes. Hypertension. 1996;27(3 pt 2):715-722.
5. Inoue K, Naruse K, Yamagami S, et al. Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. Proc Natl Acad Sci U S A. 2003;100(17):10079-10084.
6. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97(8): 4239-4244.
7. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273(5 pt 2):H2406YH2414.
8. Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kappa BYdependent mechanism. J Clin Invest. 1999;104(11):1603-1612.
9. Pikkarainen S, Tokola H, Majalahti-Palviainen T, et al. GATA-4 is a nuclear mediator of mechanical stretch Yactivated hypertrophic program. J Biol Chem. 2003;278(26):23807-23816.
10. Cameron VA, Rademaker MT, Ellmers LJ, et al. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology. 2000;141(12):4690-4697.
11. He Q, LaPointe MC. Src and Rac mediate endothelin-1 and lysophosphatidic acid stimulation of the human brain natriuretic peptide promoter. Hypertension. 2001;37(2 part 2):478-484.
12. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000;102(25):3074-3079.
13. He Q, Wang D, Yang XP, et al. Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. Am J Physiol Heart Circ Physiol. 2001;280(1):H368YH376.
14. Mukoyama M, Nakao K, Saito Y, et al. Human brain natriuretic peptide, a novel cardiac hormone. Lancet. 1990;335(8692):801-802.
15. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195-203.
16. Gerbes AL, Dagnino L, Nguyen T, et al. Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab. 1994;78(6):1307-1311.
17. LaPointe MC. Molecular regulation of the brain natriuretic peptide gene. Peptides. 2005;26(6):944-956.
18. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature. 1988;332(6159):78-81.
19. Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem. 1997;272(33):20545- 20554.
20. Yan W, Wu F, Morser J, et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide Yconverting enzyme. Proc Natl Acad Sci U S A. 2000;97(15):8525-8529.
21. Yandle TG, Richards AM, Gilbert A, et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993;76(4):832-838.
22. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49(10):1071-1078.
23. Seidler T, Pemberton C, Yandle T, et al. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun. 1999;255(2):495-501.
24. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50(9):1576-1588.
25. Schellenberger U, O'Rear J, Guzzetta A, et al. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006;451(2):160-166.
26. Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52(1):82-87.
27. Pankow K, Wang Y, Gembardt F, et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res. 2007;101(9):875-882.
28. Palmer SC, Yandle TG, Nicholls MG, et al. Regional clearance of amino-terminal pro Ybrain natriuretic peptide from human plasma. Eur J Heart Fail. 2009;11(9):832-839.
29. van Kimmenade RR, Januzzi JL Jr, Bakker JA, et al. Renal clearance of B-type natriuretic peptide and amino terminal proYB-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009;53(10):884-890.
30. Green SM, Martinez-Rumayor A, Gregory SA, et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med. 2008;168(7):741-748.
31. Moe GW, Howlett J, Januzzi JL, et al. N-terminal proYB-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115(24):3103-3110.
32. Januzzi JJL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954.
33. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
34. Steinhart B, Thorpe KE, Bayoumi AM, et al. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol. 2009;54(16):1515-1521.
35. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062-2076.
36. Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33(17):2197-2205.
37. Januzzi JL Jr, Rehman S, Mueller T, et al. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin Chem. 2010;56(12):1814-1821.
38. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal Ypro Ybrain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-2174.
39. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997-1003.
40. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52(8): 1528-1538.
41. Januzzi JL Jr, Sakhuja R, O'Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315-320.
42. Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal proYB-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090-2100.
43. Shah MR, Califf RM, Nohria A, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide Yguided therapy in patients with advanced heart failure. J Card Fail. 2011;17(8):613-621.
44. Persson H, Erntell H, Eriksson B, et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention StudyVGuidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12(12):1300-1308.
45. Karlstrom P, Alehagen U, Boman K, et al. Brain natriuretic peptide Yguided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail. 2011;13(10):1096-1103.
46. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
47. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal proYB-type natriuretic peptide Yguided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53-60.
48. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126-1130.
49. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide Yguided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16): 1733-1739.
50. Berger R, Moertl D, Peter S, et al. N-terminal proYB-type natriuretic peptide Yguided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55(7):645-653.
51. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal proYB-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881-1889.
52. Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422-430.
53. Porapakkham P, Zimmet H, Billah B, et al. B-type natriuretic peptide Yguided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170(6):507-514.
54. Bhardwaj A, Rehman SU, Mohammed AA, et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J. 2012;164(5):793-799 e1.
55. Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2012;15(3):342-351.
56. Gaggin HK, Truong QA, Rehman SU, et al. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2012 Dec 28. doi: 10.1111/chf.12016. [Epub ahead of print].